Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens.

ABSTRACT: Neoantigens, presented as peptides on the surfaces of cancer cells, have recently been proposed as optimal targets for immunotherapy in clinical practice. The promising outcomes of neoantigen-based cancer vaccines have inspired enthusiasm for their broader clinical applications. However, the individualized tumor-specific antigens (TSA) entail considerable costs and time due to the variable immunogenicity and response rates of these neoantigens-based vaccines, influenced by factors such as neoantigen response, vaccine types, and combination therapy. Given the crucial role of neoantigen efficacy, a number of bioinformatics algorithms and pipelines have been developed to improve the accuracy rate of prediction through considering a series of factors involving in HLA-peptide-TCR complex format

SUBMITTER: Hao Q 

PROVIDER: S-EPMC11281709 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature